All In Biotech

NDA 213491 · Horizon

Procysbi

Cysteamine Bitartrate · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Feb 11, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Feb 14, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

33

8 Phase 3, 2 recruiting

FAERS reports

758

403 serious, 38 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 25, 2026.

PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older. PROCYSBI is a cystine-depleting agent indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older. ( 1 )

Mechanism: Cysteamine is an aminothiol that participates within lysosomes in a thiol-disulfide interchange reaction converting cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome in patients with cystinosis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PROCYSBI · CYSTEAMINE BITARTRATE EQ 300MG BASE/PACKET · GRANULE, DELAYED RELEASE, ORAL · Prescription
  • PROCYSBI · CYSTEAMINE BITARTRATE EQ 75MG BASE/PACKET · GRANULE, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cysteamine Bitartrate" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting113
  • nausea104
  • eye irritation47
  • abdominal pain upper32
  • diarrhoea32
  • abdominal discomfort30
  • malaise28
  • death25
  • headache25
  • product dose omission issue23
  • illness22
  • amino acid level increased21

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
201415
20163
201725
201893
2019102
2020116
202178
202238
202357
2024130
202560
202639

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Procysbi (Cysteamine Bitartrate)

2024 spending

$38.0M

Beneficiaries

59

512 claims

Per beneficiary

$644,082

$174.39 per unit

View as table
YearSpending
2020$37,076,777
2021$41,249,117
2022$43,346,345
2023$39,331,261
2024$38,000,864

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.